GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
